NCT04727723 2026-03-20
REAL-LU
Novartis
Active not recruiting
Clinical Trials
10 trialsNCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT03691064 2025-12-23
SALUS
Advanced Accelerator Applications
Active not recruiting
NCT05844332 2025-12-22
LUTATHERA Injection General Use Result Survey
Novartis
Completed
NCT05459844 2025-09-05
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Phase 3 Active not recruiting
NCT06398444 2025-09-05
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Sinotau Pharmaceutical Group
Phase 2/3 Active not recruiting
NCT05816720 2023-04-18
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT02705313 2018-04-09
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Advanced Accelerator Applications
Approved for marketing